Celularity approves 1-for-10 reverse stock split.

Biotech company Celularity has approved a 1-for-10 reverse stock split of its Class A common stock to boost its share price and meet Nasdaq listing requirements. The split will take effect on February 28, 2024, and trading will begin on the Nasdaq Capital Market on a split-adjusted basis on February 29, 2024. The company's stock finished Friday's regular session up 7.1% at 46 cents.

February 23, 2024
5 Articles